Al Mann owns almost half the shares plus insiders might make a majority. Buying it out is as simple as dialing Mann's number SNY passed on that for the time being several weeks ago..
Sentiment: Strong Buy
Given the potential blockbuster potential of this drug you would think that of all people, Sanofi employees understand what may lay ahead. 385 million diabetics worldwide but 3 times the market for pre-diabetics, which is in play! I would think given the low price currently for MNKD, it would be worth investigating. Remember, that when Regeneron. got approved it went nowhere, then 4 months after FDA approval (Sanofi was already a partner) initial sell in figures came in and the stock exploded higher! Now it's a 348 dollars a share. Once sell n revenues are reported from the field that's all we need to know!
You are a physician? I hope I never have you as my doctor. Maybe you could do a little research on Afrezza before suggesting lung toxicity might be an issue. My Bydureon packaging has a long list of side effects on it which should cause you to question whether or not you should prescribe it as well.
Unfortunately us MNKD holders are taking a beating this week. It was being manipulated by a lot shorts, with 30% short float. It'll go up for sure and far beyond. Now's a great price for MNKD at $7.00. We can use your help retail investors! The fundamentals show that if only 1 Million diabetics buy Afrezza, then MNKD would be valued at $12.00/share. However, there's 382 Million diabetics worldwide! Huge potential for Sanofi and MannKind. Buy some MNKD help us get these shorts to cover.
Sentiment: Strong Buy
If you actually are a physician, I am very surprised at this late date, having so much information that is currently available, that you would make such a basic comparison of Afrezza and Exubera.
love the idea.....but how would you know if sny is accumulating mnkd shares
I'm a MNKD investor and I hope SNY IS in fact buying shares. Afrezza is going to be a huge success IMO and they are going to make bank on it.
Thank you Joey. Great answer! That is the type of financial answer I was looking for. Even with the poke at the end (I probably deserved it)
Hahaha just came over for the first time and saw this. Yes apologies in advance are in order. The knucklehead population over at the MNKD board is very high.
Surprised that nobody commented about Sanofi possibly buying shares of MannKind while the price was low. I really think that might be the situation. Also you have Medtronics that could be buying. Neither firm has to report purchasing until the next quarter. It would be a smart move of accumulation buy them if there was an eventually end of 2014 buyout.
Why don't you ask your Sanofi rep for more info on MNKD, I'm sure it will be available soon. The rep may even indicate how sales are looking, unless of course you don't have an MD and don't receive sales visits.
The perception is that SNY got a great deal on the MNKD partnership, so if you went with those who feel they picked it up for a song and you're convinced about the upside with PSCK9 inhibitor I wouldn't worry about the possibility of one countering the other...if you look at the agreement between the two entities SNY has an escape clause with notice if sales don't meet certain objectives. So if your candidate has the upside you think it does, then any upside from Afrezza would be a bonus and any downside would be limited to maybe a couple of quarters or one time writedown for a minimal amt. compared to SNY's overall earnings.
Having said all that, you really need to understand why SNY was chosen by MNKD and even more so why they signed the deal, obviously being the leader in diabetes that they are they understand its potential, and in that context you really need to open your medical mind and I am truly glad I am not a patient of yours ;-)
Sentiment: Strong Buy
Well....I was asking for an intelligent answer to my question. There have been several responses....and I am still looking for an intelligent response. I'm not looking for a medical answer (I am comfortable with my medical evaluation of the situation). I am a physician. I am looking for someone with a financial background to give an intelligent answer....If the PSCK9 inhibitor does well as I anticipate, and Alfrezza does not, what are the stock implications.......Even if you disagree with this, what do you think would happen.
FYI inhaled insulin was on the market a few years ago, it was pulled from the market by Pfizer because of poor sales. My total scripts for that product was ZERO.
So I would appreciate any intelligent response (Clevans, Creditescueny and oxotnik do not fit this criteria)
Your concerns about inhaled insulin are unfounded. It has been in use and numerous studies shows it turns into liquid upon hitting the lung surface giving the patient a ultra fast acting dose 12-15 minute and out in about a hour and a half. More physiological like natural pancreas production.
sanofi has been buying regeneron shares for a while now and i see them doing the same for mannkind
Funny how shares are trading in large chunks the last two day. Could SNY be out buying shares to eventually buy out Mannkind. They don't have ot disclose purchase less than 5% and then could actually accumulate about 20% before really disclosing if I understand the rules as disclosure doesn't occur until a reporting time? Is that correct? Many already personally controls the voting majority so it could be taken private just as easy as selling it to Sanofi for a price fair to Mann.